Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of tiragolumab added to atezolizumab + bevacizumab in untreated advanced hepatocellular carcinoma
CTR20232455Phase 3Active
- Sponsor
- Roche
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tiragolumab, atezolizumab, bevacizumab in hepatocellular carcinoma (HCC), sponsored by Roche. Started Oct 2023; status: active.
02
Drugs
tiragolumabatezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20232455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232455.